Diabetes-Induced Biochemical Changes in Central and Peripheral Catecholaminergic Systems

Physiological Research

Volumn 52, Issue 6, 2003, Pages 735-741

  Gallego, M ^a   Setien R ^a   Izquierdo, M J ^b   Casis, O ^a   Casis, E ^b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b Laboratorio Unificado de Donostia   (Spain)

Author keywords

Catecholamines; Diabetic neuropathy; Release; Storage; Synthesis

Indexed keywords

ADRENALIN; CATECHOLAMINE; DOPAMINE;

ADRENAL GLAND; ADRENALIN RELEASE; ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CATECHOLAMINERGIC SYSTEM; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE ACTIVITY; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; HEART VENTRICLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NERVOUS SYSTEM; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; RAT; SPINAL CORD; STELLATE GANGLION; SYNAPSE VESICLE;

ADRENAL GLANDS; ANIMALS; BASAL GANGLIA; BLOOD GLUCOSE; BODY WEIGHT; CATECHOLAMINES; CENTRAL NERVOUS SYSTEM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DOPAMINE; EPINEPHRINE; HEART VENTRICLES; MEDULLA OBLONGATA; MESENCEPHALON; NOREPINEPHRINE; PERIPHERAL NERVOUS SYSTEM; PONS; RATS; RATS, SPRAGUE-DAWLEY; STELLATE GANGLION; SYMPATHETIC NERVOUS SYSTEM;

EID: 0347761283     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. AHLSKOG JE, PETERSEN RC, WARING SC, ESTEBAN-SANTILLAN C, CRAIG UK, MARAGANORE DM, LENNON VA, KURLAND LT: Guamanian neurodegenerative disease: are diabetes mellitus and altered humoral immunity clues to pathogenesis? Neurology 48: 1356-1362, 1997.
2. ANAND P, TERENGHI G, WARNER G, KOPELMAN P, WILLIAMS-CHESTNUT RE, SINICROPI DV: The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 2: 703-707, 1996
3. BITAR M, KOULU M, RAPOPORT SI, LINNOILA M: Diabetes-induced alterations in brain monoamine metabolism in rats. J Pharmacol Exp Ther 236: 432-437, 1986.
4. BITAR MS, BAJIC KT, FAROOK T, THOMAS MI, PILCHER CW: Spinal cord noradrenergic dynamics in diabetic and hypercortisolaemic states. Brain Res 830: 1-9, 1999.
5. CASIS O, GALLEGO M, IRIARTE M, SÁNCHEZ-CHAPULA JA: Effects of diabetic cardiomyopathy on regional electrophysiologic characteristics of rat ventricle. Diabetologia 43: 101-109, 2000.
6. CHAUDHURI KR, HU MT, BROOKS DJ: Atypical parkinsonism in Afro-Caribbean and Indian origin immigrants to the UK. Mov Disord 15: 18-23, 2000.
7. CHU PC, LIN MT, SHIAN LR, LEU SI: Alterations in physiologic functions and in brain monoamine content in streptozotocin-diabetic rats. Diabetes 35: 481-485, 1986.
8. FERNYHOUGH P, DIEMEL LT, BREWSTER WJ, TOMLINSON DR: Altered neurotrophin mRNA levels in peripheral nerve and skeletal muscle of experimentally diabetic rats. J Neurochem 64: 1231-1237, 1995
9. FUSHIMI H, INOUE T, KISHINO B, NISHIKAWA M, TOCHINO Y, FUNAKAWA S, YAMATODANI A, WADA H: Abnormalities in plasma catecholamine response and tissue catecholamine accumulation in streptozotocin diabetic rats: a possible role for diabetic autonomic neuropathy. Life Sci 35: 1077-1081, 1984.
10. GALLEGO M, CASIS O: Regulation of cardiac transient outward potassium current by norepinephrine in normal and diabetic rats. Diabetes Metab Res Rev 17: 304-309, 2001.
11. GALLEGO M, CASIS E, IZQUIERDO MJ, CASIS O: Restoration of cardiac transient outward potassium current by norepinephrine in diabetic rats. Pflügers Arch 441: 102-107, 2000.
12. GANDO S, HATTORI Y, KANNO M: Altered cardiac adrenergic neurotransmission in streptozotocin-induced diabetic rats. Br J Pharmacol 109: 1276-1281, 1993.
13. GOTZSCHE O: The adrenergic beta-receptor adenylate cyclase system in heart and lymphocytes from streptozotocin-diabetic rats. Diabetes 32: 1110-1116, 1983.
14. GREENE D, LATTIMER S, SIMA A: Sorbitol, phosphoinositides and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 316: 599-606, 1987.
15. HART JL, FREAS W, MCKENZIE ME, MULDOON SM: Adrenergic nerve function and contractile activity of the caudal artery of the streptozotocin diabetic rat. J Auton Nerv Syst 25: 49-57, 1988.
16. HELLWEG R, HARTUNG HD: Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res 26: 258-67, 1990.
17. HILSTED J: Catecholamines and diabetic autonomic neuropathy. Diabet Med 12: 296-297, 1995.
18. HOUWING H, STRUBBE JH, BRUGGINK JE, STEFFENS AB: Sympathoadrenal activity during exercise in partial diabetic and diabetic rats. Horm Metab Res 29: 25-29, 1997.
19. JAKOBSEN J, SIDENIUS P, GUNDERSEN HJG, OSTERBY R: Quantitative changes of cerebral neocortical structure in insulin-treated long-term streptozotocin-induced diabetes in rats. Diabetes 36: 597-601, 1987.
20. JOBIDON C, NADEAU A, TANCREDE G, NGUYEN MH, ROUSSEAU-MIGNERON S: Plasma, adrenal and heart catecholamines in physically trained normal and diabetic rats. Diabetes 34: 532-535, 1985.
21. KAUL CL, GREWAL RS: Increased urinary excretion of catecholamines and their metabolites in streptozotocin diabetic rat. Pharmacology 21: 223-228, 1980.
22. KNIEL PV, JUNKER U, PERRIN I, BESTETTI GE, ROSSI GI: Varied effect of experimental diabetes on the autonomic nervous system of the rat. Lab Invest 54: 523-530, 1986.
23. KURATA C, OKAYAMA K, WAKABAYASHI Y, SHOUDA S, MIKAMI T, TAWARHARA K, SUGIYAMA T: Cardiac sympathetic neuropathy and effects of aldose reductase inhibitor in streptozotocin induced diabetic rats. J Nucl Med 38: 1677-1680, 1997.
24. KWOK RPS, JUORIO AV: Concentration of striatal tyramine and dopamine metabolism in diabetic rats and effect of insulin administration. Neuroendocrinology 43: 590-596, 1986.
25. LUCAS PD, QUIRBI A: Tissue noradrenaline and polyol pathway in experimentally diabetic rats. Br J Pharmacol 97: 347-352, 1989.
26. MONCKTON G, PEHOWICH E: Autonomic neuropathy in the streptozotocin diabetic rat. Can J Neurol Sci 7: 135-142, 1980.
27. OZTURK Y, ALTAN VM, ILDIZOGLU-ARI NY: Effects of experimental diabetes and insulin on smooth muscle functions. Pharmacol Rev 48: 69-112, 1996.
28. PAULSON DJ, LIGHT KE: Elevation of serum and ventricular norepinephrine content in diabetic rat. Res Commun Chem Pathol Pharmacol 33: 559-562, 1981.
29. SATO N, HASHIMOTO H, TAKIGUCHI Y, NAKASHIMA M: Altered responsiveness to sympathetic nerve stimulation and agonists of isolated left atria of diabetic rats: no evidence for involvement of hypothyroidism. J Pharmacol Exp Ther 248: 367-371, 1989.
30. SCHMIDT RE, PULARD SB: Ultrastructural and biochemical characterisation of autonomic neuropathy in rats with chronic streptozotocin diabetes. J Neuropathol Exp Neurol 45: 525-544, 1986.
31. SHIMOMURA Y, SHIMIZU H, TAKAHASHI M, SATO N, UEHARA Y, SUWA K, KOBAYASHI I, TADOKORO S, KOBAYASHI S: Changes in ambulatory activity and dopamine turnover in streptozotocin-induced diabetic rats. Endocrinology 123: 2621-2625, 1988.
32. SINGH NP, PUGAZHENDHI V, DAS AK, PRAKASH A, AGARWAL SK: Clinical and laboratory profile of diabetes in elderly. J Indian Med Assoc 97: 124-128, 1999.
33. TOMLINSON DR, YUSOF AP: Autonomic neuropathy in the alloxan diabetic rat. J Auton Pharmacol 3: 257-263, 1983.
34. TOMLINSON KC, GARDINER SM, HEBDEN A, BENNETT T: Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol Rev 44: 103-150, 1992.
35. 3H] spiroperidol binding in streptozotocin-diabetic rats. J Neurochem 40: 1456-1459, 1983.
36. WILKE RA, HILARD CJ: Decreased adrenal medullary catecholamine release in spontaneously diabetic BB-Wistar rats. Role of hypoglycaemia. Diabetes 43: 724-729, 1994.
37. YOSHIDA T, NISHIOKA H, NAKAMURA Y, KONDO M: Reduced noradrenaline turnover in streptozotocin induced diabetic rats. Diabetologia 28: 692-696, 1985.